Mark Poulton

Senior Consultant, GxPAssure

Mark Poulton is a dedicated and adaptable professional with extensive expertise in Clinical Quality Management and Clinical Project Management. Mark is committed to upholding the highest standards of compliance, operational efficiency, and delivery excellence across all projects. With a proven track record in leading quality initiatives and managing complex global projects, Mark supports organisational objectives through strong analytical and problem-solving skills.

Recognised for exceptional communication and presentation abilities, Mark excels at translating complex concepts into clear, actionable insights for a wide range of stakeholders. As a confident and supportive team manager, Mark fosters collaboration, motivates colleagues, and promotes a positive team culture. Known for strong interpersonal skills, reliability, and a proactive work ethic, Mark is highly proficient in leveraging information technology to streamline processes and enhance productivity within clinical and quality operations.

Key areas of expertise include:

• Clinical Quality Management
• Clinical Project Management
• Communication & Presentation
• Problem Solving & Risk Identification
• Team Management & Leadership
• Interpersonal Skills & Stakeholder Engagement
• Quality Systems & Regulatory Compliance
• Information Technology to Enhance Productivity

With multiple industry publications to his name, Mark has contributed original research and insights to respected journals and international conferences, including:

• Archives of Virology (1983): Some characteristics of Mycoplasma virus
• Journal of Antibiotics (1989): A Novel Series of Milbemycin Antibiotics from Streptomyces Strain E225 I. Discovery, Fermentation and Anthelmintic Activity
• Journal of Antibiotics (1990): A Novel Series of Milbemycin Antibiotics from Streptomyces Strain E225 II. Isolation, Characterisation, Structure Elucidation & Solution Conformations
• VIII International Conference on AIDS, Amsterdam (1992): Mode of Action of BRL 47923, A Potent and Selective Inhibitor of HIV Replication

These publications reflect Mark’s commitment to advancing scientific understanding and sharing knowledge within the professional community.